Comments on Palivizumab (Synagis)
- 1 February 1999
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP)
- Vol. 103 (2) , 495-496
- https://doi.org/10.1542/peds.103.2.495
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Humanized Monoclonal Antibody for Prevention of Respiratory Syncytial Virus InfectionPublished by American Academy of Pediatrics (AAP) ,1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin ProphylaxisPediatrics, 1997
- Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young ChildrenNew England Journal of Medicine, 1993